High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: a retrospective evaluation

@article{Demirer2003HighdoseTM,
  title={High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: a retrospective evaluation},
  author={Taner Demirer and Veli Uysal and Meltem Aylı and Yasemin Genç and Osman Ilhan and Haluk Koç and Mehmet Daǧlı and M. Ali Arat and Nazan Gunel and Turgay Fen and Suleyman Dincer and Nilufer Ustael and Mustafa Y{\'i}ld{\'i}z and Tulay Ustun and Ertuğrul Seyrek and Gulsum Ozet and Osman Muftuoglu and Hamdi Akan},
  journal={Bone Marrow Transplantation},
  year={2003},
  volume={31},
  pages={755-761}
}
Summary:This study was conducted to evaluate the efficacy of high-dose thiotepa, melphalan and carboplatin (TMCb) regimen in 27 patients undergoing autologous stem cell transplantation (ASCT) for metastatic breast cancer. A total of 27 patients with stage IV breast cancer underwent ASCT following thiotepa (500 mg/m2), melphalan (100 mg/m2) and carboplatin (1200–1350 mg/m2). Of 27 patients, 17 had refractory relapse, eight had responding relapse, and two had no evidence of disease (NED) at the… CONTINUE READING